In order to provide you with relevant and meaningful content we need to know more about you.
Please choose the category that best describes you.
This content is intended for U.S. Healthcare Professionals. Would you like to proceed?
If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.
Distributed by Hospira, Inc., Lake Forest, IL 60045 USA
Magnesium Sulfate in 5% Dextrose Injection is indicated for:
Magnesium Sulfate in 5% Dextrose Injection is:
Magnesium Sulfate in 5% Dextrose Injection, USP is a clear and colorless to slightly yellow solution supplied in single-dose bags:
Magnesium Sulfate in 5% Dextrose Injection is contraindicated in patients:
Continuous administration of magnesium sulfate beyond 5 to 7 days in pregnant women can lead...
The following adverse reactions have been identified in clinical studies or postmarketing reports. Because these reactions are reported voluntarily from a population of uncertain size, it is not always...
Table 1 presents the potential clinical impact of medications that may be commonly administered concomitantly with Magnesium Sulfate in 5% Dextrose Injection in the clinical setting.
Magnesium Sulfate in 5...
Manifestations of magnesium toxicity include a drop in blood pressure, difficulty breathing, and disappearance of the patellar reflex. As serum magnesium rises above 4 mEq per liter, the deep tendon reflexes...
Magnesium Sulfate in 5% Dextrose Injection, USP is a sterile, nonpyrogenic solution of magnesium sulfate heptahydrate and dextrose in water for injection for intravenous use. Each 100 mL contains 1 gram of...
Magnesium prevents seizures in patients with preeclampsia and controls seizures in patients with eclampsia by...
Studies with Magnesium Sulfate in 5% Dextrose Injection have not been performed to...
Magnesium Sulfate in 5% Dextrose Injection, USP is a clear solution supplied in single-dose flexible plastic containers (see Table 2).
Magnesium Sulfate in 5% Dextrose Injection is typically administered to pregnancy women in emergent situations. When feasible, advise the patient and family of the following:
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Contact Medical Information. 8AM-9PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
To report an adverse event related to Pfizer-BioNTech COVID-19 Vaccine (also known as COMIRNATY®, COVID-19 mRNA, Vaccine BNT162b2 or BNT162) or Pfizer COVID-19 Treatment (also known as PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)), and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site
*If you are involved in a clinical trial for either product, adverse events should be reported to your coordinating study site.